Literature DB >> 3003220

Effect of ketoconazole on adrenocorticotrophic hormone secretion in vitro and in vivo.

J M Burrin, T H Yeo, M J Ashby, S R Bloom.   

Abstract

The direct effects of ketoconazole on ACTH secretion have been investigated using a rat pituitary cell culture system. Ketoconazole had no significant effects on basal ACTH secretion, corticotrophin-releasing factor- or arginine vasopressin-stimulated ACTH secretion, nor did it affect dexamethasone inhibition of ACTH secretion. In-vivo studies demonstrated an increased ACTH level (168 vs 76 ng/l) accompanied by a fall in plasma corticosterone (193 vs 307 micrograms/l) in normal rats given ketoconazole (24 mg/kg, five oral doses given 8 hourly). No effects were seen in adrenalectomized rats or at lower doses (6 mg/kg) in normal or adrenalectomized rats. A high dose of ketoconazole (24 mg/kg, twice daily oral doses) also caused increased ACTH levels in normal rats (129 vs 86 ng/l) when given for 7 days. No effects were seen in adrenalectomized rats or on plasma corticosterone levels in normal rats. Our data suggest that ketoconazole at these doses has no direct effects on pituitary ACTH secretion but causes an increase in plasma ACTH due to its inhibition of adrenal steroid synthesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3003220     DOI: 10.1677/joe.0.1080037

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats.

Authors:  M C Moffett; N E Goeders
Journal:  Psychopharmacology (Berl)       Date:  2006-11-21       Impact factor: 4.530

Review 2.  Medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 3.  The endocrine effects of ketoconazole.

Authors:  N Sonino
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

Review 4.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

Review 5.  Recent developments in drug therapy for Cushing's disease.

Authors:  Rob van der Pas; Wouter W de Herder; Leo J Hofland; Richard A Feelders
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

6.  Ketoconazole treatment in Cushing's disease. Effect on the circadian profile of plasma ACTH and cortisol.

Authors:  M Terzolo; M Panarelli; A Piovesan; M Torta; P Paccotti; A Angeli
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

7.  The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats.

Authors:  Ruba S Darweesh; Tamam El-Elimat; Aref Zayed; Tareq N Khamis; Wahby M Babaresh; Tawfiq Arafat; Ahmed H Al Sharie
Journal:  BMC Pharmacol Toxicol       Date:  2020-11-16       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.